Drug shortages have worsened globally since 2021; the US had 323 active shortages in early 2024, with most exceeding two years and affecting at least 500,000 patients.

France logged 4,925 shortages in 2023, and 44% of people faced shortages in 2024.

Most countries saw worsening shortages in 2022, prompting EU coordination; starting in 2024, the EU launched voluntary medicine sharing, early warning, joint procurement, and broader pharmaceutical-law reforms. [3].

In 2024, vulnerable categories include generics, chemotherapy agents, stimulants, antimicrobials, hormonal agents, and IV fluids; anticoagulants and some emergency medicines have limited-substitute shortages, and amoxicillin, ibuprofen, and paracetamol/acetaminophen have run short in multiple countries. [1].

More than a dozen oncology drugs, including cisplatin and carboplatin, are critically scarce, affecting an estimated 10–20% of cancer patients, and regulators allowed temporary FDA authorization to import chemotherapy drugs like cisplatin to ease shortages.

99% of hospital pharmacists report shortages, and one in three health systems has delayed or rationed care; US cancer care has diverted and rationed drugs, with shortages averaging 18 months and some lasting up to 15 years. [4].

ADHD drugs such as Adderall have been scarce since October 2022 due to manufacturing delays, rising demand, and production limits, and rising demand and limited active ingredients have constrained drugs like Ozempic and ADHD stimulants. [6].

The Russia–Ukraine war and sanctions disrupted logistics and raw materials, raising prices and causing scarcities.

Manufacturing and quality problems are leading causes, and economic pressures, industry consolidation, and reliance on foreign manufacturing increased vulnerability. [1].

Proactive steps include creating a medication list, monitoring inventory, and discussing backup regimens with prescribers, and experts recommend establishing safety stocks for critical medicines. [14].

Drug shortages have worsened globally since 2021; the US had 323 active shortages in early 2024, with most exceeding two years and affecting at least 500,000 patients.

Title:

Content: General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
An Unexpected Catastrophe in the World ’ s Largest Country: The Complete Story of U.S. Drug Shortages
The deficit is at a record level.
According to data from the American Society of Health System Pharmacists and the University of Utah Drug Information Service, organizations began tracking drug shortages for the first time in 2001. Steady since 2021 – now reaching a record high of 323 drugs in the first three months of 2024.
Paul Abramowitz, CEO of the American Society of Health System Pharmacists, wrote in a blog post on Thursday: “It ’ s been a long time to end drug shortages, ” and wrote:“ All drug classes are vulnerable to shortages, some of the most worrisome shortages include sterile injectable generic drugs, including cancer chemotherapy drugs and emergency drugs stored in hospital vans and procedural areas. It is dangerous for doctors and patients. ”
In addition to the 32 chemotherapy drugs that are deficient, the five categories of drugs with the greatest deficiency include central nervous system stimulants, antimicrobials, hormonal agents, and intravenous fluids. [1] The Drug Deficiency Database maintained by the American Society of Health System Pharmacists and the University of Utah is based on voluntary reports from practitioners, patients, and others that have been confirmed by manufacturers. The U.S. drug is in short supply, because it captures broader effects on service providers and patients.
The crisis has lasted a year and a half.
More than half of the treatment shortages have lasted for more than two years, according to an analysis by health consultancy IQVIA, and the average shortage affects at least half a million patients, many of them elderly, according to the US Office of Health and Human Services under the Assistant Secretary for Planning and Evaluation, which shared its analysis with Congress in May.
Growing demand can play a role in drug shortages, as with the recent shortage of weight-loss drugs, but often manufacturing and quality problems, such as supply chain gaps and downtime, are the root cause. And varied.
But the American Society of Health System Pharmacists has “serious concerns ” about parts of this proposal, especially financial sanctions imposed on hospitals that lack the resources to comply with the recommendations, Abramowitz wrote:“ We all know that managing shortages is not enough and is not a sustainable solution to the worsening crisis, and there is still a lot of work to be done at the federal level to fix the root causes of drug shortages. ”
Why Shortage Occurs
Shortages can be caused by high demand, as with the recent shortage of weight-loss drugs, but this is not usually the main problem.
The FDA also blames manufacturing and quality problems, supply chain gaps, and downtime, and Dr. Emily Tucker, a drug shortage expert and an assistant professor of industrial engineering at Clemson University, says that when there is an indication of shortages, large health systems often also proactively place large orders, adding to the system ’ s stress.
“I don ’ t blame anyone.
“When I talk to all the stakeholders – whether it ’ s wholesalers, manufacturers, or the government – everyone wants this problem to end, ” she said.
Lack of transparency
Dr. Julie Grallo, chief medical officer and executive vice president of the American Society of Clinical Oncology, told the House Committee earlier that the shortage puts providers in a terrible position: “The drug shortage crisis is forcing providers to make impossible choices, and it is also hindering the development of new drugs. Health drugs are purchased only on a price basis, and manufacturers do not have to disclose the source of their acquisition of the ingredients.
The shortage of this generic chemical drug came due to the closure of one factory in India that manufactures the active ingredient after a surprise FDA inspection found “significant quality issues, ” says Jarallo:“ We didn ’ t know, and there was no transparency regarding the company ’ s supply of the majority of active pharmaceutical ingredients to all manufacturers across the board.
Knowing this in advance, we could have responded much faster, ” Dr. Steven Schundlemeyer, director of the PRIME Institute of the University of Minnesota School of Pharmacy, which focuses on economic and management issues, told the committee that as with defense contractors in the United States, New Zealand requires manufacturers to disclose their suppliers, and that information is required.
Easily accessible in the database.
Related Topics

France logged 4,925 shortages in 2023, and 44% of people faced shortages in 2024.

Title:

Content: French health groups put forward proposals to limit the damage of worsening drug shortages

Medicines such as cough syrup, lozenges and ointment are seen on a table in an apartment in Berlin, Tuesday, December 20, 2022. Copyright Stephanie Pilick/dpa via AP
Copyright Stephanie Pilick/dpa via AP
By Lauren Chadwick
Share this articleComments
Share this article

Pharmaceutical companies’ lack of transparency leads to rising drug prices and less control over public resources, the group of health organisations say.

ADVERTISEMENT

A group of French organisations have called for more transparency from pharmaceutical companies as drug shortages increase.

In a joint report, 14 civil society organisations outlined their recommendations to solve a “situation that has only worsened” since 2018.

The French medicines regulator signalled 4,925 drug shortages in 2023, compared to 3,761 in 2022 and 2,160 in 2021.

A 2024 survey from France Assos Santé, which represents patients, found that 44 per cent of people in France said they had faced a drug shortage this year.

One of the pharmacy unions in France has even planned a strike at the end of the month over drug shortages and what they say is worsening access to care.

Each health organisation contributed an article with recommendations for dealing with the drug shortages.

The League Against Cancer urged complete transparency on drug shortages and potential substitutions for health professionals.

They also called for monitoring of medicine stocks and their location in the country to guarantee equal access.

The organisation found in a survey published in February that 78 per cent of health professionals in oncology had been faced with a drug shortage.

Drug shortages or delays have led to anxiety among cancer patients, lost time, and worsening symptoms, the organisation said.

France Assos Santé, meanwhile, wrote that an urgent response should not be to support “the industrial sector which bears serious responsibilities” for abandoning the production of less profitable drugs, relocating drug production, and keeping insufficient medicine stocks.

They would like any cost increases justified by production costs or the risk of withdrawing a drug from the market due to it being unprofitable. They called for cost evaluations to be made public.

Their concerns also range from the use of public money to bring drug production to Europe to new government plans to prevent shortages.

Some changes at the EU level criticised

Last year, the European Commission announced several measures to reform the pharmaceutical industry and address critical drug shortages.

The European Parliament went on to adopt a position on pharmaceutical reform last month, that included “incentives for innovation” and an effort to limit overuse of antibiotics.

The non-profit organisation Prescrire, which focuses on information about medicine, wrote in a chapter they contributed to the report that while some of the European Commission’s measures were welcome, others were concerning.

One of the many measures they rejected included the Commission’s proposal to reduce the number of days of scientific evaluation of drugs from 210 to 180, which they said was necessary time rather than an “administrative obstacle”.

While the NGO welcomed some measures such as government drug shortage prevention plans, it said the Commission should allow EU states to require pharmaceutical companies to have safety stocks of medicine and sanction those that do not respect them.

ADVERTISEMENT

French consumer organisation UFC-Que Choisir and the European Consumer Organisation (BEUC) said that they had hoped MEPs would shorten the length of time for “data protection” to allow generic medicines to be marketed more quickly.

Instead, MEPs approved shortening the period to 7.5 years, “which is almost the same duration as the current 8 years [yet] within the framework of the text adopted by Parliament, companies can gain additional months of protection under certain conditions to reach a total of 8.5 years,” UFC-Que Choisir said.

Share this articleComments

You might also like

Most countries saw worsening shortages in 2022, prompting EU coordination; starting in 2024, the EU launched voluntary medicine sharing, early warning, joint procurement, and broader pharmaceutical-law reforms. [3].

Title:

Content: There is not enough medicine in the EU
19 January 2023, 05: 20
ASTANA.
KAZINFORM - The European Union is suffering from a shortage of medicines.
Deficiency of antibiotics, such as amoxicillin, drugs against colds, flu and other respiratory infections, as well as some drugs for children, reports MIA "Kazinform" with reference to euronews.com.
In most countries, the situation is considered critical, but since such goods from pharmacies do not disappear at all, citizens are not advised to make stocks.
Doctors note a weakening in the population of natural immunity due to protection against coronavirus such as social distancing.
The main reasons for the sharp increase in demand, which have been identified, is the high prevalence of respiratory diseases with a lack of production capacity.
As pharmaceutical issues are being addressed at the national level, Governments are already taking steps to overcome the shortage
These measures include the sale of generics and the replacement of requested medicines with similar ones.
In some countries, some formulations have been changed, for example, drugs are offered in the form of syrups instead of tablets, so that children are more willing to take them.
"Pediatric drugs are generally now less available in the form of conventional tablets," said Steffen Tierstrup, chief medical officer of the European Medicines Agency. "Therefore, where children are more ill, the need for pediatric drugs is higher than for adult drugs."
A recent study showed that the shortage of drugs in Spain increased by 38% over the year.
The decline in their production was affected by inflation, high energy prices, shortages of raw materials and the effects of the pandemic.
“We need diversification, ” said Ilaria Passarani, head of the EU Pharmaceutical Group.“ Of course, it would be useful to return to Europe the production of some critical materials, such as active ingredients.
But we can't return all the production of all the materials we use for drugs.
This entails problems such as the increase in pharmacy prices associated with the implementation of environmental laws, labor laws, which are not necessarily enforced in other regions. ”
In March, the European Commission will present a revised version of the EU pharmaceutical legislation, which will include stricter supply obligations, earlier notification of shortages and seizures of medicines, and better informing the public about available stocks.
News on the topic
Partners news
News feed

In 2024, vulnerable categories include generics, chemotherapy agents, stimulants, antimicrobials, hormonal agents, and IV fluids; anticoagulants and some emergency medicines have limited-substitute shortages, and amoxicillin, ibuprofen, and paracetamol/acetaminophen have run short in multiple countries. [1].

Title:

Content: This website uses relevant technologies to provide a better reading experience, while respecting the privacy of users. Click here to understand the privacy statement of the Central News Agency. When you close this window, you agree to the above regulations.
Your browser does not appear to support Traditional Chinese.
Would you like to go to CNA ’ s English website, “Focus Taiwan ”?
Koko Koko Koko Koko Koko Koko
"日本語版「フィーカス」について" (in Japanese).
Central News First-hand News APP
Download
Health Insurance Department: Most of the new list of missing drugs is included in the price range
2023 / 2 / 25 14: 26 (Updated 2 / 25 14: 45)
Please agree to our privacy policy in order to enable news listening.
Lack of medicine is frequent, recently extended from the community pharmacy to the hospital, the National Health Insurance Department pointed out on the 25th, after comparing the medical profession to introduce a new list of shortage of drugs, most of them are not included in the adjustment.
(Image taken from Pixabay library)
Please agree to our privacy policy in order to enable news listening.
(Central News Agency reporter Shen Peiyao, Taipei, 25) The shortage of medicines has been frequently reported, and it has recently been extended from community pharmacies to hospitals.
The Health Insurance Department pointed out today that after comparing the list of new medicines in the medical sector, most of them are not adjusted, and some are machine and freight problems, and supply has been resumed gradually.
According to the "Drug Expenses Target System", the Central Health Insurance Administration of the Ministry of Health and Welfare adjusts the budget of health insurance drugs every year.
Due to the COVID-19 (COVID-19) pandemic, the health insurance drug budget has not been adjusted for two years, and the combined adjustment amount of 110 and 111 is NT $8.18 billion. The original plan was announced yesterday and took effect on April 1, but it was temporarily cancelled.
Health Insurance Commissioner Shi Chongliang yesterday said that the current health insurance contains about 14,000 drugs, the original has been good, is expected to adjust 6009 of them, the remaining 8000 do not adjust, because the medical sector also proposed a number of drugs to obtain difficulties, has brought back the list, but also need a little time to re-examine and calculate, so the announcement was postponed.
Chen Yu-ying, deputy secretary general of the All Federation of Pharmacists Association, said in a telephone interview today that although there is no complete shutdown, the manufacturers will have a slight control on the supply volume, and there is no way to supply the full amount.
Chen Yuying said that in a large hospital, a total of about 34 drugs need to be replaced by other brands, and the supply of the most is only the usual 70 to 80%, including antibiotics "amoxicillin" (Ampicillin), Ampicillin (Ampicillin), etc., as well as anti-allergic drugs, blood pressure drugs, and muscle relaxants for intubation during surgery.
The biggest headache for hospitals is the shortage of anticoagulant drugs.
Chen Yuying said that there are other drugs that can be replaced by oral drugs, but there is only one manufacturer of anticoagulants, one formulation, and another brand will have to be replaced when stocks are exhausted. The mechanism of the drug is not the same, "There is no substitute at all in the clinic, but there is a change in the way."
In response to the shortage of medicines in the hospital, Huang Yu-wen, head of the medical audit and pharmaceutical section of the National Health Insurance Administration, explained that when he communicated with representatives of the medical community on the relevant issues yesterday, the Taiwan Community Hospital Association provided 58 items of shortage drugs, and compared, most of the drugs have not been adjusted in the principle of drug price adjustment.
As for a small number of drugs that are not included in the scope of adjustment, Huang Yu-wen says that most of them are three identical products (the same ingredients, dosage, and content) that have been accepted by Health Insurance for more than 15 years, or have other alternatives for the same indications, and some of the shortage of drugs is due to short-term production problems, such as drug packaging machine failures and shipping delays.
Huang Yuwen said that the initial assessment of medical representatives to put forward a new list of shortage of drugs, does not affect the current price adjustment, will still be announced on March 1. At present, health insurance has received about 14,000 drugs, of which 6009 items, 8.18 billion yuan is expected to be adjusted. (Editor: Li Hengshan) 1120225
Central News Agency "First-hand News" app
The text, pictures and audio and video of this website shall not be reproduced, broadcast or transmitted or used without authorization.

More than a dozen oncology drugs, including cisplatin and carboplatin, are critically scarce, affecting an estimated 10–20% of cancer patients, and regulators allowed temporary FDA authorization to import chemotherapy drugs like cisplatin to ease shortages.

Title:

Content: As drug shortage list grows, many hospitals face tough decisions on rationing care

More than half of hospital pharmacists are reporting a critical shortage of chemotherapy drugs and nearly all are reporting overall medicine supply gaps as prescription drug shortages near an all time high, according to a new survey.

Hospital pharmacists said drug shortages have forced 1 in 3 health systems to delay, cancel or ration care or switch to alternate drugs to continue to treat patients. And 99% are reporting some drug supply shortages, an American Society of Health-System Pharmacists survey of more than 1,000 pharmacists released Thursday found.

The organization reported shortages of 309 drugs, near the all-time high of 320 shortages in 2014. The scarcity of key drugs is prompting hospitals to find or substitute drugs and change treatment plans as needed.

“In some cases, there are no alternatives to the affected drugs, which puts patients at risk," ASHP Chief Executive Officer Paul W. Abramowitz said in a statement. "This issue requires quick action from Congress to address the underlying causes of shortages and ensure patients have the medications they need.”

Cancer drug shortages

In June, the Food and Drug Administration said it will temporarily allow overseas drug manufacturers to import some chemotherapy drugs.

The FDA allowed Qilu Pharmaceutical, a drug manufacturer in China, to import the injectable chemotherapy drug cisplatin in 50-milligram vials. Toronto pharmaceutical company Apotex Corp. will distribute the medication in the United States.

More than a dozen cancer drugs have been in shortage in recent months, including cisplatin and carboplatin, used to treat lung, breast, prostate and gynecologic cancers. The National Cancer Institute said cisplatin and similar drugs are prescribed for 10% to 20% of all cancer patients.

In June, the National Comprehensive Cancer Network released a survey of 27 academic cancer centers that found 93% reported shortages of carboplatin and 70% faced shortages of cisplatin.

When cancer hospitals face such shortages, they attempt to make sure there's enough medication for patients to finish the course of treatment, said Mike Ganio, ASHP's senior director of pharmacy practice and quality.

Cancer hospitals facing such shortages might change medications for new patients starting on chemotherapy, said Ganio, a former pharmacy manager at an academic cancer center.

"You try to keep that patient on the same regimen as much as you can, unless they're failing it for some reason, and then you would switch," Ganio said.

Steroids, hormonal drugs also in short supply

More than 1 in 5 hospital pharmacists also reported shortages for steroids, hormonal drugs and oral liquids such as lidocaine, ibuprofen and amoxicillin.

A smaller number of pharmacists said heart medications, emergency prefilled syringes and drugs used for intensive care unit patients were in short supply. Others reported shortages of attention deficit hyperactivity disorder medicines, antimicrobial drugs and injectable opioids.

In all, about two-thirds of pharmacists said the shortages were "moderately impactful," which means they are managing shortages but patients are affected.

Pharmacists are managing the shortages by offering therapeutic alternatives, buying different vial sizes or concentrations and rationing medicines.

This article originally appeared on USA TODAY: Survey: Drug shortages are widespread, hospitals ration care

99% of hospital pharmacists report shortages, and one in three health systems has delayed or rationed care; US cancer care has diverted and rationed drugs, with shortages averaging 18 months and some lasting up to 15 years. [4].

Title:

Content: The New York Times Original
Continue reading Growing drug shortage in the United States has become a threat to national security
The shortage of medicines in the United States last year increased compared to 2021 by 30%, according to The New York Times.
However, the article notes that the growing shortage of inexpensive but critical drugs poses a national security threat to the United States.
The growing shortage of inexpensive but critical drugs poses a threat to U.S. national security and forces hospitals to make “terrible ” choices, writes The New York Times, citing a report prepared for hearings in the U.S. Senate.
According to this report, the shortage of medicines last year increased by almost 30% compared to 2021, with an average shortage of medicines observed for 18 months, and for some drugs – 15 years.
Among the drugs in short supply are conventional antibiotics and anesthetics, the article said.
Senator Gary Peters, a Democrat from Michigan and chairman of the Senate Committee on Homeland Security and Government Affairs, said that these problems are related to economic factors, an opaque supply chain and the fact that 80% to 90% of some products are made abroad.
“Taken together, these underlying causes not only raise serious concerns about ensuring proper patient care, but also pose a serious threat to national security, ” Peters said.
Dr. Andrew Schumann, an oncology surgeon from Michigan, told senators at the hearing that the shortage of drugs in his field is "a tragedy occurring in slow motion."
As Schumann noted, recently due to the shortage of one cheap, but well-proven cancer drug, he had to choose which patients will receive this drug.
The article notes that many of the cheapest drugs tend to be made in countries such as India and China, where they are inexpensive to manufacture.
However, this concentration of production capacity creates an additional level of vulnerability to problems such as natural disasters and political unrest, emphasizes The New York Times.
The materials of InoTV contain estimates of exclusively foreign media and do not reflect the position of RT
We publish on Twitter relevant foreign articles selected by the editorial office of InoTV
source
New York Times United States of America
tags
disease india china medicine usa
Today in the media
Popular
INFOX.SG
RT News Feed
Partners news

ADHD drugs such as Adderall have been scarce since October 2022 due to manufacturing delays, rising demand, and production limits, and rising demand and limited active ingredients have constrained drugs like Ozempic and ADHD stimulants. [6].

Title:

Content: Clara Pitts has always strived for perfection.

The 17-year-old Utah native has been named a 2023 National Merit Scholarship finalist. And she heads to Brigham Young University as a freshman this fall.

But despite all of her achievements, Clara has one thing weighing on her mind: What if she fails?

Clara was diagnosed with attention-deficit/hyperactivity disorder (ADHD) in 10th grade, during the summer of 2020, after months of digital schooling had started to take its toll.

"For the first time, I started struggling with getting my homework done [and] having a set schedule that I had to do myself," Clara said. "It was because of online school."

So along with her mother, Rebekah, she made the decision to try medication.

"I didn't realize just how much my ADHD was inhibiting me from acting the same way as all of my friends until I had that experience of leveling the playing field," Clara said.

By December 2020, Clara was prescribed 10 milligrams of Adderall, a formulation of amphetamine mixed salts, to be taken twice a day. Immediately, she noticed a difference.

"It seemed like the logical course of action, like something that shouldn't have been happening in my brain was being fixed," Clara said. "Naturally, my brain goes really, really fast, and I don't even notice it because it's what I've grown up with, and it's the only mind I've ever experienced. But once I started having a different experience mentally, I felt a lot calmer."

For the two years that followed, Clara was finally able to lead what she called a normal life, managing school, extracurricular activities and social life -- all with the help of Adderall.

But in October 2022, Clara's sense of calm was stripped away when the US Food and Drug Administration announced a shortage of Adderall and its generic counterparts.

"I hadn't heard anything about a shortage," she said. "I didn't really take it seriously at first until later that week -- maybe three or four days later -- when I started to hear news about the shortage, and it really started to sink in."

CNN first spoke with Clara and her mother, Rebekah, about a month after the FDA's announcement. At the time, Clara had eight Adderall pills left in her prescription bottle -- enough to last her four days.

"Initially, I was just very surprised when I tried to refill the prescription and they would not [refill it]," Rebekah says. "Very quickly, I went from surprised to afraid."

On October 24, Rebekah texted Clara the bad news. The shortage had finally affected them, and their pharmacy could not refill Clara's medication due to the shortage.

"They wouldn't put you on a waiting list," Rebekah texted her daughter. "I'm just sitting here crying because I can't get you these meds."

Rebekah says she called eight local pharmacies, and each one turned up empty.

"I felt really emotional about it in that first week or two ... like I had failed my child, even though it wasn't my fault," Rebekah said. "I felt scared for what that would mean for her as a senior."

Why is there a shortage?

The FDA announced a shortage of Adderall on October 12. The agency noted that it was in communication with all manufacturers of amphetamine mixed salts and that one of those companies, Teva, was "experiencing ongoing intermittent manufacturing delays." Although other manufacturers continued to produce the drug, the agency said, "there is not sufficient supply to continue to meet U.S. market demand through those producers."

Jim McKinney, a spokesperson for the agency, told CNN that the manufacturing delay has been resolved and that the shortage is now "demand-driven."

Data from the analytics and research company IQVIA shows that the demand for Adderall has risen nearly 27% in recent years, with prescriptions jumping from 35.5 million in 2019 to 45 million last year.

On its website, the FDA lists eight manufacturers that have reported Adderall shortages to the agency. The website lists the shortage reason for some versions of the drug, such as "demand increase" or "shortage of active ingredient," but for other versions, it just says "other" or lists no reason at all.

Each year, the Drug Enforcement Administration tracks and sets a limit on production of amphetamine, one of the key ingredients in Adderall. It says that for the past three years, manufacturers didn't expend all of the ingredients that were available for their use.

"DEA is committed to ensuring that all Americans can readily access needed medications," an agency spokesperson told CNN in a statement. "We are aware that the pharmaceutical industry is claiming that there is a quota shortage for the active ingredients in ADHD drugs. Based on DEA's information -- which is provided by drug manufacturers -- this is not true."

CNN reached out to the eight manufacturers that reported shortages to the FDA.

Teva Pharmaceuticals, Epic Pharma and Rhodes Pharmaceuticals did not respond. Alvogen, SpecGX and Sunrise Pharmaceutical declined to comment.

Sandoz said it had enough product to meet current customer orders. Lannett also said it had enough to meet current customer orders but added that it did not have enough to fulfill increased demand.

McKinney, the FDA spokesperson, said supply is increasing.

"The FDA recognizes the potential impact that reduced availability of certain products may have on health care providers and patients and is working closely with numerous manufacturers and others in the supply chain to understand, mitigate and prevent or reduce the impact of intermittent or reduced availability of certain products," he said.

McKinney clarified that although the FDA is working with manufacturers, the agency does not make drugs and "cannot require a pharmaceutical company to make a drug, make more of a drug, or change the distribution of a drug."

Dr. Yoram Unguru, a pediatric hematologist and oncologist with joint faculty appointments at the Herman & Walter Samuelson Children's Hospital at Sinai and the Johns Hopkins Berman Institute of Bioethics, studies drug shortages.

He says a lack of transparency about details -- how big the shortage is and how much drug each company is making -- is hindering solutions.

"Pharmaceutical manufacturers are not required to disclose the reason for disrupted supply. Knowing the exact reason for a given shortage is always challenging," Unguru said. "It's really difficult to be able to anticipate and let alone come up with meaningful solutions if you don't know what the problem is."

The search for alternatives

Clara ultimately went without Adderall for two and half months as she coped with the stresses of senior year. She began taking a different ADHD medication, Vyvanse, in mid-January.

Rebekah says she hopes Adderall will be an option for Clara again one day, adding that she doesn't have the emotional stamina to keep searching for the medication.

"I would like her to have medication as an option and for it to be reliable, because college will probably be the hardest journey for her with ADHD."

Clara says that life without Adderall is like trying to see the world vividly while wearing smudged glasses.

"You go around with dirty glasses. You get used to it, and you don't realize that they're dirty. But when you clean them off, having that extra bit of clarity makes a world of difference."

The-CNN-Wire

™ & © 2023 Cable News Network, Inc., a Warner Bros. Discovery Company. All rights reserved.

CNN's Raenu Charles and Janelle Chavez contributed to this report.

0
0
0
0
0

Recommended for you

The Russia–Ukraine war and sanctions disrupted logistics and raw materials, raising prices and causing scarcities.

Title:

Content: There are problems, but there will be no shortage: pharmacies explained why there are not always the necessary drugs on sale
The ongoing war, unjustified growth in demand and problems with production lead to a short-term absence of certain drugs in pharmacies.
Martial law imposes additional difficulties on the import of medicines, but Ukrainian pharmaceutical companies have practically solved this problem: they produce 61% of medicines from the National List of Medicines.
About this Delo.ua told pharmacists and manufacturers.
In the pharmacy holding ANC explain that they fix several main reasons why some positions may disappear in the network:
1.
Due to the martial law in the country, the supply of goods from abroad is irregular, because not every carrier is ready to transport the goods to a country where hostilities continue;
2.
In such cases, insurance companies do not cover the transportation of goods due to high risks;
3.
Completion of the registration period of the goods;
4.
The company producing the goods decided to leave the Ukrainian market.
While data on foreign trade are available only in the context of 4 digits of the code UKTVED, more detailed statistics are not published in the conditions of martial law.
But these data also indicate a reduction in the supply of drugs from abroad, which was confirmed in Goslikluzhba.
Pharmacists note that they do not affect suppliers or the supply of goods.
If the drug is absent from the main distributors, the pharmacist can only recommend analogues to the client in the positions that he can offer.
“At the same time, unfortunately, there is no alternative for unique imported drugs.
Probably, if the state provided manufacturers and suppliers with additional guarantees, this could change the situation, ” adds Maria Semenova.
At the same time, as noted in the pharmaceutical company "Darnitsa", with temporary problems with the presence of a foreign medicine, Ukrainian manufacturers can offer generics of similar quality.
Pharmacists agree that manufacturers are successfully closing the gap in the market, but note that they do not produce innovative new drugs of the latest generations and original drugs, as well as drugs necessary for the treatment of rare diseases.
At the same time, the reduction of imports of medicines to Ukraine has a positive effect - it contributes to the growth of the production of domestic medicines.
Because, as noted in "Darnitsa", an increase in the production of domestic drugs leads to GDP growth, the number of jobs and tax revenues to the country's budget.

Manufacturing and quality problems are leading causes, and economic pressures, industry consolidation, and reliance on foreign manufacturing increased vulnerability. [1].

Title:

Content: International
International News
Dependent on foreign raw materials fluctuate, big pharmaceutical companies chase short-term profit loss production
The shortage of ADHD drugs is just the tip of the iceberg of the current drug shortage in the United States. According to the FDA, more than 135 drugs are in short supply, including chemotherapy drugs for cancer.
A survey released by the American Society of Health System Pharmacists (ASHP) in early August showed that one-third of the 1,100 hospitals surveyed had no prescription, delayed or reduced prescriptions due to drug shortages to meet the supply window.
Expert analysis, pharmaceutical companies to pursue short-term profit first business model, so that the production of life-saving drugs and demand out of line, drug shortage problem is difficult to improve.
Experts urge pharmaceutical companies to face social responsibility
Rita Numerof, a medical industry consultant, wrote in Forbes magazine that in order to reduce costs, US pharmaceutical companies have long relied on foreign suppliers such as China, India and Italy to import raw materials for the production of drugs, which is prone to fluctuations in supply. They are looking to develop drugs that are more likely to be used for long-term diseases.
Teva, a manufacturer of ADHD drugs and the world ’ s largest generic drug manufacturer, announced earlier that it would reduce the production of some generic drugs and focus on more profitable products. Rumelove warned that if pharmaceutical companies are unwilling to address their social responsibilities and strengthen supply risk management, public trust in the pharmaceutical industry will continue to weaken, and ultimately public health and safety will pay a heavy price.
Focus on the organization to accelerate the use of new generic drugs to increase production incentives
The American Association for Access to Medicines (AAM) released a report last month, saying that because of restrictions on the supply of generic drugs, the supply price of generic drugs is limited, and the return of investment in new drugs is not high. The situation.
(Forbes / DrugTopics)
(Global Hot Talk)
Related Words: Adderall Drug Shortage Attention Deficit and Hyperactivity Disorder (ADHD)
Previous / Next News

Proactive steps include creating a medication list, monitoring inventory, and discussing backup regimens with prescribers, and experts recommend establishing safety stocks for critical medicines. [14].

Title:

Content: A body calls on the Ministry of Health to face the shortage of medicines and the absence of some in pharmacies
Hiba Press Lace
The Moroccan Network for the Defense of the Right to Health and the Right to Life called on the Ministry of Health and the Directorate of Medicines to impose the law on the reserve stock of medicines and medical supplies on laboratories and wholesale distributors, and to have a strategic stock of health materials within the framework of national sovereignty.
In a statement, the health network warned that citizens have returned to Marton to move between pharmacies to search for missing drugs, which are in high demand at this time of the year, as well as medicines for chronic diseases.
The network attributed the loss of drugs in the national market to the failure of a number of laboratories, companies and wholesale drug distributors to respect a safety stock equal to 1 / 12 of their total sales during the previous year, and the failure of some of these laboratories to respect the law that requires securing the reserve stock, to avoid the interruption of medicine, medical supplies and blood derivatives from the national market.
To overcome this situation, the statement called on the Ministry of Health and the Directorate of Medicines to demand that companies, laboratories and distributors of medicines wholesale, must create a safety stock of at least two months for all medicines of major therapeutic importance for patients in Morocco, within the framework of a national plan to combat drug shortages and ensure access to these essential medicines for patients at all times and at reasonable prices.
What do you think?
Total 0 Reviews
0.
Did you like it!
+ = Verify Human or Spambot?
Related Articles
Go to the top button
CLOSE